



FOR IMMEDIATE RELEASE

Eisai London Research Laboratories Licenses OriGene's FlagArray™ for Genome-Wide Functional Analyses

Rockville, MD August 1, 2005 – OriGene Technologies Inc. today announced that Eisai London Research Laboratories has licensed OriGene's FlagArray platform for high-throughput drug target discovery.

"We are pleased to formalize our relationship with OriGene," said Yukio Nishizawa, PhD, Director of Research for Eisai London Research Labs. "We believe OriGene's FlagArray to be an innovative technology that will prove an excellent platform for use in our discovery programs."

The OriGene FlagArray(s) are expression-ready arrays of full-length cDNA plasmids for use in high-throughput, genome wide target identification and validation. The arrays allow scientists to easily query thousands of genes and their roles in disease phenotypes and pathways. This platform has been used by several leading pharmaceutical companies providing numerous discoveries. One example of the power of this system can be seen in Proc. Natl. Acad. Sci., 2005, pp 1927-32.

"OriGene's mission is to build the most comprehensive collection of human full-length cDNAs in expression ready vectors and to apply this collection to systematic studies of human gene functions to all researchers," said Karl Kovacs PhD, Vice President of Alliance Management at OriGene. "We are pleased to support the drug discovery and target validation efforts at Eisai with the FlagArray platform. The ability to over-express and test the effects of thousands of proteins will provide important leads to understanding complex intra-cellular interactions."

About Eisai London Research Laboratories

Eisai London Research Laboratories Ltd. (ELL), a research-based drug discovery laboratory established in 1990, is located within the fertile environment of University College London, UK. Its parent company, Eisai Co., Ltd., Japan's fourth largest pharmaceutical company, counts Aricept®, and Pariet® /Aciphex®, amongst its major developments. ELL's multinational team is positioned at the start of the path that leads from research bench to patient treatment. ELL is dedicated to creating innovative medicines, directed at novel targets, to satisfy the increasing unmet medical need in neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease and multiple sclerosis to enhance the quality of human life. In this endeavour, the needs of the patient, their caregivers and families are paramount. For more information about Eisai, please visit <http://www.eisai.co.jp>

About OriGene Technologies

OriGene provides innovative technologies for large-scale gene function analyses. OriGene's flagship product is the TrueClone Collection, a searchable source of over 24,000 human full-length cDNA clones suitable for transfection and protein expression. More information about OriGene Technologies, the FlagArray(s) and their other products can be found at the company's web site at <http://www.origene.com>.

For additional information regarding this announcement, please contact:

Rich Hamer, Ph.D.
Business Development
OriGene Technologies 240-620-5781
rhamer@origene.com